3MM Stock Overview
A specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Advicenne S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.99 |
| 52 Week High | €2.97 |
| 52 Week Low | €1.12 |
| Beta | 1.11 |
| 11 Month Change | 6.30% |
| 3 Month Change | n/a |
| 1 Year Change | 13.33% |
| 33 Year Change | -72.89% |
| 5 Year Change | -79.10% |
| Change since IPO | -82.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3MM | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.9% | 1.6% | 1.1% |
| 1Y | 13.3% | -19.0% | 7.2% |
Return vs Industry: 3MM exceeded the German Pharmaceuticals industry which returned -18.3% over the past year.
Return vs Market: 3MM exceeded the German Market which returned 8.6% over the past year.
Price Volatility
| 3MM volatility | |
|---|---|
| 3MM Average Weekly Movement | 16.2% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3MM's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3MM's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 21 | Didier Laurens | www.advicenne.com |
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. Its main drug candidate is Sibnayal, which has completed phase III clinical trial for the treatment of distal renal tubular acidosis, as well as cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures.
Advicenne S.A. Fundamentals Summary
| 3MM fundamental statistics | |
|---|---|
| Market cap | €25.43m |
| Earnings (TTM) | -€8.83m |
| Revenue (TTM) | €3.33m |
7.6x
P/S Ratio-2.9x
P/E RatioIs 3MM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3MM income statement (TTM) | |
|---|---|
| Revenue | €3.33m |
| Cost of Revenue | €2.22m |
| Gross Profit | €1.11m |
| Other Expenses | €9.94m |
| Earnings | -€8.83m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 27, 2025
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 33.33% |
| Net Profit Margin | -264.93% |
| Debt/Equity Ratio | -102.2% |
How did 3MM perform over the long term?
See historical performance and comparison